Literature DB >> 3839362

Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues.

R V Lloyd, M Blaivas, B S Wilson.   

Abstract

The distribution of chromogranin and S100 protein was studied in 30 adrenal pheochromocytomas and 19 normal adrenal medullary tissues. Immunostaining in the tumors was compared with staining in sections of histologically normal medullae. Chromogranin showed diffuse cytoplasmic staining in all chromaffin cells. Chromogranin staining was consistently more intense in normal medullae, while less intense staining was present in most tumors from all four groups. S100 protein was present in the cytoplasm and nuclei of sustentacular cells surrounding chromaffin cells and in nerve branches. Many S100 protein-positive cells were present in normal medullae, in the two hyperplastic medullae, and in pheochromocytomas from patients with multiple endocrine neoplasia, type 2. Very few sustentacular cells were present in the other pheochromocytomas. These results indicate that S100 staining may be helpful in separating pheochromocytomas in patients with multiple endocrine neoplasia, type 2 disease from benign and malignant sporadic tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839362

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  31 in total

1.  Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.

Authors:  Kalman Kovacs; David Bell; Geoffrey W Gardiner; R John Honey; Jeannette Goguen; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Immunocytochemical localization of NCAM and catecholamine-synthesizing enzymes in rabbit intra- and extra-adrenal chromaffin tissue.

Authors:  A Moftaquir; K Langley; M J Boutroy
Journal:  Histochem J       Date:  1996-10

3.  Immunohistochemical identification and comparison of glial cell lineage in foetal, neonatal, adult and neoplastic human adrenal medulla.

Authors:  G Magro; S Grasso
Journal:  Histochem J       Date:  1997-04

4.  Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.

Authors:  Noriko Kimura; Toshiya Watanabe; Takao Noshiro; Soichiro Shizawa; Yukio Miura
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 5.  Differential diagnosis of pheochromocytomas and paragangliomas.

Authors:  A M McNichol
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Non-functional malignant paraganglioma of the stomach.

Authors:  C Schmid; A Beham; P Steindorfer; L Auböck; F Waltner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

7.  Risk Stratification in Paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and Immunohistochemical Markers.

Authors:  Maithili Mandar Kulkarni; Siddhi Gaurish Sinai Khandeparkar; Sanjay D Deshmukh; R R Karekar; Vandana L Gaopande; Avinash R Joshi; Mrunal V Kesari; R R Shelke
Journal:  J Clin Diagn Res       Date:  2016-09-01

8.  Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.

Authors:  Nobue Kumaki; Hiroshi Kajiwara; Kaori Kameyama; Ronald A DeLellis; Sylvia L Asa; R Yoshiyuki Osamura; Hiroshi Takami
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130.

Authors:  Jan-Hermen Dannenberg; Leontine Schuijff; Marleen Dekker; Martin van der Valk; Hein te Riele
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

10.  Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells.

Authors:  George Kontogeorgos; Bernd W Scheithauer; Kalman Kovacs; Eva Horvath; Sclomo Melmed
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.